At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 20 enrolled
Drug / intervention
PF-06741086biological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A MULTICENTER, OPEN-LABEL STUDY TO EVALUATE THE LONG-TERM SAFETY, TOLERABILITY AND EFFICACY OF SUBCUTANEOUS PF-06741086 IN SUBJECTS WITH SEVERE HEMOPHILIA
In Brief
A Phase 2 clinical trial evaluating PF-06741086 for Hemophilia A or B. Completed, enrolled 20 participants across 8 sites in 7 countries.
Detailed Summary
This study is designed to evaluate the safety, tolerability and efficacy of long-term treatment with PF-06741086 in subjects with severe hemophilia who participated in the 3-month Phase 1b/2 B7841002 study. Additionally, de novo subjects will be recruited into this study.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHemophilia A or B
CountriesBrazil, Chile, Croatia, Poland, South Africa, Switzerland, United States
Collaborators--
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedDec 2017
Enrollment StartMay 2018
Primary CompletionAug 2020
TodayJul 2026
First PostedDec 6, 2017
Enrollment StartMay 30, 2018
Primary CompletionAug 5, 2020
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 8.6 years ago
Interventions
PF-06741086biological
PF-06741086 subcutaneous injection